AGMB
AgomAb Therapeutics NV
NASDAQ · Healthcare · Biotechnology · BE
$8.23
−0.60%Oct 1, 2026, 10:30 UTC
Agomab Therapeutics announced positive topline results from the 48-week open-label extension of the Phase 2a STENOVA trial of ontunisertib in patients with fibrostenosing Crohn's disease, supporting a planned global Phase 2b NOV-ERA study.
Sep 14, 2026, 20:05 UTC
Agomab Therapeutics announced positive Phase 1 results for AGMB-447 in idiopathic pulmonary fibrosis patients and submitted a CTA for the Phase 2 INSPIRIA study, which it intends to initiate before year-end.
Source: